Eunice L. Kwak

TL;DR: In patients with advanced, ALK-positive NSCLC, crizotinib therapy is associated with improved survival compared with that of crizotib-naive controls, and ALK rearrangement is not a favourable prognostic factor in advanced NSClC.

TL;DR: A sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) is reported in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without theALK translocation, which support the dependence of ALk-rearranged tumors on AlK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor.

TL;DR: After neoadjuvant FOLFIRINOX imaging no longer predicts unresectability, traditional pathologic predictors of survival are improved, and morbidity is decreased in comparison to patients with clearly resectable cancers at the time of presentation.

TL;DR: In an analysis of frozen tissue specimens, IDH1 mutation was associated with highly elevated tissue levels of the enzymatic product 2-hydroxyglutarate, defining a specific metabolic abnormality in this largely incurable type of gastrointestinal cancer and present a potentially new target for therapy.

TL;DR: Sunitinib shows evidence of modest antitumor activity in advanced HCC with manageable adverse effects and Rapid changes in tumor vascular permeability and circulating inflammatory biomarkers are potential determinants of response and resistance to sunitinIB in HCC.